Financial Data and Key Metrics Changes - Total revenue increased by 12.4% to $503.4 million, driven by all three segments [17] - Adjusted EBITDA grew to $154.9 million, up 23.9% compared to the prior year [18] - Adjusted earnings per share rose to $2.43, a 34.3% increase year-over-year [19] - Operating cash flow generation for the trailing twelve months was $428 million, up $146 million from the previous year [20] Business Line Data and Key Metrics Changes - Chamberlain reported revenue of $183.8 million, a 1.6% increase, but total student enrollment declined by 1% [22] - Walden's revenue increased by 27% to $217.6 million, with total student enrollment up 13% [23] - Medical and Veterinary segment revenue was $102 million, a 6.9% increase, with adjusted EBITDA rising by 17.6% [25] Market Data and Key Metrics Changes - Total enrollment grew over 6% to 97,000 students, marking the tenth consecutive quarter of enrollment growth [4][7] - Chamberlain's pre-licensure BSN programs have seen growth for 14 consecutive quarters, while post-licensure programs faced declines [22] - Walden's growth was particularly strong in behavioral sciences and nursing programs [32] Company Strategy and Development Direction - The company is focused on addressing the healthcare workforce crisis by expanding capacity and creating new revenue streams [7] - A disciplined, returns-focused approach to capital allocation is being maintained, with $165 million deployed for share repurchases [4] - The upcoming Investor Day will outline a multi-year growth framework [7][47] Management's Comments on Operating Environment and Future Outlook - The healthcare workforce crisis is intensifying, with significant gaps expected to deepen, particularly in rural and underserved areas [6][7] - Management remains confident in achieving full-year revenue guidance of 6%-8.5% growth and has raised adjusted EPS guidance to 17%-20% growth [4][27] - The company expects application growth at Chamberlain to translate into future enrollment growth [27] Other Important Information - The company has approximately $728 million remaining on its current share repurchase authorization [4] - Adjusted EBITDA margin expanded by 290 basis points to 30.8% [18] - The one-week academic calendar shift contributed an additional $18 million in revenue for Walden in Q2 [17][26] Q&A Session Summary Question: Can you provide insights on Walden's growth and market share? - Management noted that growth is consistent across programs, particularly in behavioral sciences and nursing, indicating potential market share gains [32] Question: What is the status of the partnership with Sallie Mae regarding loan caps? - Management confirmed they are working on definitive documentation for the partnership and are optimistic about its implications for the portfolio [33] Question: Can you elaborate on Chamberlain's enrollment trends and lead times? - Management acknowledged recent improvements in application volumes and expressed confidence in returning to positive enrollment growth by the fall cycle [39][40] Question: What factors could lead to exceeding the high end of revenue guidance? - Management indicated that quicker recovery at Chamberlain and acceleration in the Med Vet segment could contribute to exceeding guidance [42]